An In Vitro Microneutralization Assay for SARS‐CoV‐2 Serology and Drug Screening
Fatima Amanat, Kris M. White, Lisa Miorin, Shirin Strohmeier, Meagan McMahon, Philip Meade, Wen‐Chun Liu, Randy A. Albrecht, Viviana Simon, Luis Martínez‐Sobrido, Thomas M. Moran, Adolfo García‐Sastre, Florian Krammer
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS-CoV-2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS-CoV-2 in vitro. © 2020 Wiley Periodicals LLC. Basic Protocol 1: Microneutralization assay to test inhibition of virus by antibodies (purified antibodies or serum/plasma) Basic Protocol 2: Screening of anti-SARS-CoV-2 compounds in vitro Support Protocol: SARS-CoV-2 propagation.